{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:57:29Z","timestamp":1781254649271,"version":"3.54.1"},"reference-count":65,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Transformed follicular lymphoma (t-FL) is an aggressive lymphoma with limited prospective evidence to guide treatment, particularly in the relapsed setting. We summarized the current evidence on emerging cellular and targeted therapies that extend beyond conventional chemoimmunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This scoping review was conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA-ScR) and structured using the Population\u2013Concept\u2013Context (PCC) framework. Adults with histologically confirmed or strongly suspected t-FL were the population of interest. Findings were synthesized narratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventeen studies met inclusion criteria across three therapeutic categories: CAR-T therapy (7 interventional trials, n\u2009=\u2009130 t-FL patients in reported subsets), CD20\u00d7CD3 bispecific antibodies (BsAbs; n\u2009=\u200961 t-FL patients with extractable outcomes), and selinexor (n\u2009=\u200931 t-FL patients); together encompassing approximately 222 t-FL patients across primary interventional cohorts with extractable outcomes. CAR-T products achieved overall response rates (ORR) of 52\u201383% and complete response (CR) rates of 40\u201358%; randomized second-line trials favored axicabtagene ciloleucel and lisocabtagene maraleucel over standard care. In real-world CAR-T series, ORR ranged from 82\u201392% and CR rates from 64\u201367% across registry cohorts. BsAbs were active in heavily pretreated disease (epcoritamab ORR 50%\/CR 44%; glofitamab ORR 55%\/CR 35%), with predominantly low-grade cytokine release syndrome. Selinexor showed more modest efficacy (ORR 39%\/CR 16%) but durable benefit in complete responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current evidence supports a stepwise treatment framework: DLBCL-like induction at transformation, autologous stem-cell transplant in fit, chemosensitive responders, CAR-T as the preferred option at first relapse, BsAbs after CAR-T or when cellular therapy is not feasible, and selinexor in later-lines of therapy. Additional prospective t-FL\u2013inclusive trials are needed to refine treatment selection and biomarker-guided sequencing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748261454479","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:02:50Z","timestamp":1781071370000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-5302","authenticated-orcid":false,"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"first","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola","family":"Ghasoub","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrouq","family":"Hwafdeh","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000115"},{"issue":"4","key":"e_1_3_8_4_2","first-page":"757","article-title":"Utilizing clinical transformation criteria for prognostic stratification in follicular lymphoma prior to initial immunochemotherapy","volume":"16","author":"Alderuccio JP","year":"2024","unstructured":"Alderuccio JP, Lossos IS, Rodrigues E, et al. Utilizing clinical transformation criteria for prognostic stratification in follicular lymphoma prior to initial immunochemotherapy. Hematol Rep. 2024;16(4):757-768.","journal-title":"Hematol Rep"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7120"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013499"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3990"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621375"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7163"},{"key":"e_1_3_8_10_2","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu SS","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307-2315.","journal-title":"Blood"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00339-4"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198714"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000975796.49668.c2"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025015834"},{"key":"e_1_3_8_23_2","first-page":"2178","article-title":"Outcomes of CD19 CAR T in transformed indolent lymphoma compared to de novo aggressive large B-cell lymphoma","volume":"99","author":"Thiruvengadam SK","year":"2024","unstructured":"Thiruvengadam SK, Merryman R, Wang Y, et al. Outcomes of CD19 CAR T in transformed indolent lymphoma compared to de novo aggressive large B-cell lymphoma. Am J Hematol. 2024;99:2178-2187.","journal-title":"Am J Hematol"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1307242"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1567149"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0"},{"key":"e_1_3_8_27_2","first-page":"1472","article-title":"Bispecific antibodies in follicular lymphoma","volume":"110","author":"Nizamuddin IA","year":"2025","unstructured":"Nizamuddin IA, Bartlett NL. Bispecific antibodies in follicular lymphoma. Haematologica. 2025;110:1472-1482.","journal-title":"Haematologica"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014375"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03481-y"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1035"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.5603\/hicp.98431"},{"key":"e_1_3_8_32_2","volume-title":"FDA approves selinexor for relapsed\/refractory diffuse large B-cell lymphoma including transformed follicular lymphoma","author":"U.S. Food and Drug Administration","year":"2020","unstructured":"U.S. Food and Drug Administration. FDA approves selinexor for relapsed\/refractory diffuse large B-cell lymphoma including transformed follicular lymphoma. FDA; 2020. [Regulatory approval reference; efficacy data from SADAL trial, ref 25]."},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.12.027"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-649905"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.175"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0016-8"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.02.006"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018719"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3473"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-512392"},{"key":"e_1_3_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30090-5"},{"key":"e_1_3_8_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000258"},{"key":"e_1_3_8_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0839"},{"key":"e_1_3_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.011"},{"key":"e_1_3_8_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024496"},{"key":"e_1_3_8_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020999"},{"key":"e_1_3_8_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_3_8_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09054.x"},{"key":"e_1_3_8_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"e_1_3_8_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35378"},{"key":"e_1_3_8_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"e_1_3_8_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.5671"},{"key":"e_1_3_8_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.072"},{"key":"e_1_3_8_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283"},{"key":"e_1_3_8_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026016"},{"key":"e_1_3_8_57_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281461"},{"key":"e_1_3_8_58_2","volume-title":"B-cell lymphomas","author":"NCCN Clinical Practice Guidelines in Oncology","year":"2025","unstructured":"NCCN Clinical Practice Guidelines in Oncology. B-cell lymphomas. Version; 2025."},{"key":"e_1_3_8_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu537"},{"key":"e_1_3_8_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt029"},{"key":"e_1_3_8_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12570"},{"key":"e_1_3_8_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_3_8_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_8_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_3_8_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn657"},{"key":"e_1_3_8_66_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology. B-cell lymphomas. Version 2025. National Comprehensive Cancer Network."}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748261454479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748261454479","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748261454479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:16:43Z","timestamp":1781252203000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748261454479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":65,"alternative-id":["10.1177\/10732748261454479"],"URL":"https:\/\/doi.org\/10.1177\/10732748261454479","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/10732748261454479\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261454479\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261454479\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261454479\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261454479\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261454479\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"10732748261454479"}}